You are here
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership governance consists of an Executive Committee and four working groups. Each of the four working groups identify and develop criteria, goals, and objectives and review progress and milestones. The working groups are managed by the Foundation for the National Institutes of Health (FNIH) and report to the ACTIV Executive Committee. An ACTIV Partnership Leadership Group, which includes representatives from all the ACTIV partners as well as the Executive Committee members, also regularly reviews the progress of ACTIV.
The Executive Committee is comprised of scientific executives representing both U.S government agencies and industry. It is responsible for overseeing the activities and operations of the four working groups, including reviewing evaluations of experimental agents recommended for preclinical testing and clinical trials by the four working groups and the master protocols designed to test them.
Charge: Create an integrated preclinical framework to evaluate existing drugs and drug candidates that require preclinical evaluation for both repurposing and development of novel therapeutics.
Charge: Prioritize therapeutic agents for testing within an adaptive master protocol strategy that will be jointly designed by the partnership and quickly launched in networks identified by the Clinical Trial Capacity Working Group.
Charge: Develop a full inventory of clinical trial capacity, including networks from NIH Institutes and Centers, industry, and contract research organizations (CROs), that will serve as potential settings in which to implement effective COVID-19 clinical trials.
Charge: Accelerate evaluation of vaccine candidates by supporting harmonized clinical efficacy trials and a parallel effort to generate biomarkers and other evidence for more rapid approval/authorization.
Charge: Provide actionable intelligence on SARS-CoV-2 variants through genomic surveillance, data sharing and curation, and standardized in vitro assessments of therapeutics against novel strains.
This page last reviewed on June 21, 2021